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Key Points IVLBCL is a rare subset of DLBCL that presents a unique diagnostic dilemma that delays diagnosis and 
impacts outcome. Improvements in diagnostic testing are needed to improve time from symptom onset to diagnosis in 
an effort to improve clinical outcomes.
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Abstract: 
Intravascular large B-cell lymphoma (IVLBCL) is a rare entity, with a generally aggressive 
course that may vary based on geographic presentation. While a United States (US) registry 
study showed relatively good outcomes with IVLBCL, clinicopathological and treatment data 
were unavailable. We performed a detailed retrospective review of cases identified at 8 US 
medical centres, to improve understanding of IVLBCL and inform management.  We compiled 
data retrieved via an Institutional Review Board-approved review of IVLBCL cases identified 
from 1999-2015 at nine academic institutions across the US. We characterized the cohort's 
clinical status at time of diagnosis, presenting diagnostic and clinical features of the disease, 
treatment modalities used and overall prognostic data.  Our cohort consisted of 54 patients with 
varying degrees of clinical features. Adjusting for age, better performance status at presentation 
was associated with increased survival time for the patients diagnosed in vivo (hazard ratio: 2.12, 
95% confidence interval 1.28, 3.53). Based on the data we have collected, it would appear that 
the time interval to diagnosis is a significant contributor to outcomes of patients with IVLBCL.
Introduction
Intravascular large B-cell lymphoma (IVLBCL) is a rare disease with a body of literature built 
primarily upon single case studies and a collection of small case series. Initially described by 
Pfleger and Tappeiner (1959), IVLBCL is now recognized as a distinct subtype of mature B-cell 
lymphoma. The disease is characterized by lymphomatous involvement of small vessels, 
typically without significant or any extravascular disease, with a high incidence of central 
nervous system (CNS) involvement.
The ability of IVLBCL to affect any organ system is well documented, and the resulting 
occlusion of the microvasculature in the afflicted organ makes the signs and symptoms of the 
disease particularly heterogeneous and notoriously difficult to diagnose. Previous retrospective 
studies have recognized the presence of distinct phenotypes within the disease. The Classical, or 
Western, variant presents with evidence of neurological involvement and cutaneous findings 
(Ferreri et al 2004) The Asian variant is associated with bone marrow infiltration and 
haemophagocytic syndrome without overlapping classical features (Murase et al 1997,2000).  A 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved
‘cutaneous variant’, representing isolated limited skin involvement, was described by Ferreri et 
al (2004) and tends to occur in young female patients with retained performance status. 
Historically, IVLBCL has been known to have a rapidly progressive and fatal course.  To date, 
no diagnostic markers or imaging studies have been validated to detect the presence of IVLBCL, 
and diagnosis requires biopsy of an affected organ. As such, patients frequently present for 
treatment late in the disease course with disseminated involvement. A previous study from Japan 
appeared to indicate that treatment could be improved with the addition of rituximab to frontline 
therapy (Shimada et al 2008), but this has yet to be verified in any large studies.  In Western 
variants, survival was markedly better in those able to receive standard anthracycline-based 
therapy plus rituximab (3-year overall survival [OS]: 89% vs. 38%; Ferreri et al 2008). The 
cutaneous variant is associated with better outcomes potentially due to its underlying biology vs. 
visible evidence of disease leading to more accessible sites for biopsy (Ferreri et al 2004; Röglin 
& Böer 2007). A significant number of IVBCL cases (34% to 60%) are first diagnosed at time of 
autopsy depending upon the affected organ systems.  
Given the overall rarity of the disease, with an incidence recently estimated at 0.095 per 1 
million per year (SEER 2000-2013), no prospective studies have evaluated treatment strategies. 
Emerging work has demonstrated that with timely treatment, particularly with the addition of 
CD20-directed therapy, outcomes may be more similar to those seen in diffuse large B-cell 
lymphoma (DLBCL) than historically anticipated. Indeed, a recent United States registry study 
demonstrated that patients with IVLBCL had survival outcomes comparable to DLBCL-not 
otherwise specified (NOS) in the rituximab era although specific clinical, pathological, and 
treatment data were unavailable given the nature of the analysis (Rajyaguru et al 2016). In order 
to gain further insight into the prognosis of IVLBCL and its management, we report on a 
multicentre, retrospective review of 54 IVLBCL patients diagnosed across nine academic 
medical centres in the US and compare these data with five previously published studies of 
IVLBCL.  
Methods
We performed a retrospective analysis of data retrieved via IRB-approved review of IVLBCL 
cases identified at nine academic institutions across the United States.  Only adult patients with 
histologically confirmed IVLBCL between 1999-2015 were included.  
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved
Collected information included: demographic information, clinical symptoms, date and site of 
diagnosis, biochemical data, staging information, bone marrow involvement including presence 
of haemophagocytosis, molecular markers, treatment regimens used (including first, second and 
third line therapies and transplantation status), and clinical outcomes. The Ann Arbor staging 
system was used in disease staging. Response to therapy, described as complete remission (CR), 
sustained disease (SD) or progressive disease (PD), was determined by the contributing 
institutions.  
We collected OS data from five previously published studies of IVLBCL (Brunet et al 2017; 
DiGiuseppe et al 1994; Ferreri et al 2004; Hong et al 2013; Murase et al 2007). When the 
patient-level data was not provided in these reports, we used the GraphClick software 
(http://www.arizona-software.ch/graphclick/) to extract the fitted survival probabilities from the 
published Kaplan-Meier plots. The studies used various methods to incorporate post-mortem 
diagnoses, including reporting OS as time from presentation of symptoms to death.
Statistical Analysis
Descriptive statistics are presented for continuous and categorical variables. OS was calculated 
as time from diagnosis to death or loss to follow-up. Patients in our study population were 
retrospectively grouped into two categories: post-mortem diagnosis (i.e. OS of “0 months”) or in 
vivo diagnosis. Survival curves and median survival time were estimated using the Kaplan-Meier 
method, both for all patients and the subset of patients who were recorded to have received 
treatment. We fit univariable Cox proportional hazard models for patients diagnosed in vivo to 
determine the associations of sex, white blood cell count, International Prognostic Index (IPI), 
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), and lactate 
dehydrogenase (LDH) per 100-unit increase with survival, adjusting for age. All analyses were 
conducted in R version 3.4.3 (R Core Team 2018).
Results
Patient Demographics
Our cohort consisted of 54 patients, including 23 men and 30 women (Male:Female ratio of 0.77 
and one individual whose sex was not recorded), with varying degrees of clinical data available 
(Table I). Race and ethnicity of individual cases were unknown. Median age at time of diagnosis 
was 63 years (range 40-88 years). For patients with performance status (PS) data available, the 
median ECOG PS at presentation was 2, with 62% of patients having PS greater than 1.  For 
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deceased patients/those diagnosed post mortem, we utilized the PS from the time of initial 
presentation/hospitalization. Of the 17 patients with scores of 0-1, 7 (41%) were noted to have 
primarily cutaneous findings.  Staging per the Ann Arbor staging system (Rosenberg 1977; 
Moormeier et al 1990) was available for 45 patients, with all but 6 (87%) presenting with stage 
IV disease. 
The most common symptom type was non-specific systemic B-symptoms, such as fevers, night 
sweats or weight loss for 29 of the 44 patients assessed (66%). Neurological symptoms were 
present in 41% (18/43) of patients and included altered mental status or confusion (23%), 
weakness (18%), headache (14%), stroke symptoms (12%), paresthesia (9%), vision changes 
(9%) and seizure (5%).  Skin involvement, including rash, cutaneous nodules and 
haemangiomas, was seen in 9 patients (21%). Respiratory symptoms including shortness of 
breath, cough and respiratory failure were noted in 21% of patients (n=9).  Gastrointestinal 
symptoms consisted of abdominal pain (n=3) and ascites (n=1). Two patients had evidence of 
endocrinopathy on presentation, including panhypopituitarism (n=1) and goitre (n=1). Imaging 
data was not available for correlation of presenting symptoms or organ involvement with specific 
radiographic findings.  
Primary diagnosis was made at time of autopsy in 6 patients and in vivo for 35 patients. Time of 
diagnosis was not available for the remaining patients.  The most common site of disease 
identification in vivo was in the CNS, either by brain biopsy (n=10) or identification of atypical 
cells in the cerebrospinal fluid (n=2).  The bone marrow was the primary diagnostic site in 10 
patients. Of the 11 patients that were diagnosed by skin biopsy, only 9 patients had documented 
cutaneous findings at that time. Other sites of primary pathological diagnosis included lung 
(n=5), liver (n=3), gastrointestinal tract (n=3), muscle (n=3), spleen (n=2), genito-urinary tract 
(n=2), temporal artery (n=2) and thyroid (n=1). 
A total of 43 patients had record of a bone marrow biopsy performed with 26 (60%) patients 
having IVLBCL in the bone marrow. Haemophagocytosis was seen in 12% of patients (n=5); 
15% of the total patients had unreported data (n=8). Organomegaly was present in 20 patients 
and in 58% of patients with bone marrow involvement. Conversely, for those with organomegaly 
who underwent bone marrow biopsy, 93% had concurrent bone marrow involvement (14/15). 
The occurrence of bone marrow involvement in patients without organomegaly was 38%. 
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Immunophenotypic markers that were available for review varied between cases (Table II). CD5 
positivity was seen in 50% of the reported cases (n=28). CD10, MUM1 and BCL6 were used to 
determine cell of origin (COO) in 28 patients who had all the required data via the Hans 
algorithm (Hans et al 2004). Using this algorithm, the COO was determined to be non-germinal 
centre (GC) B-cell in 82% of these cases.  High-risk markers, BCL2 and MYC were evaluated, 
but collection was sporadic, with MYC being reported in only 8 of the cases with 63% of those 
being positive.  We had a total of 15 reports of BCL-2 expression, with 80% of those being 
positive.  Results of fluorescence in situ hybridisation (FISH) testing was not available to 
evaluate for the occurrence of double hit lymphoma in our population but, given the majority of 
patients with data classified as non-GC by COO, we would expect very few patients to possess 
this molecular abnormality.  On the other hand, we would expect a higher percentage of patients 
to potentially classify as “double expressers”, but with our limited collection of this information 
in the entire cohort only four patients were noted to have expression of both markers. 
Laboratory Findings
Patients frequently presented with an elevated LDH at time of first diagnosis (median 576 iu/l), 
interquartile range 338.0-1459.8). This contributed to a median IPI score at time of diagnosis of 
4 (60% of patients presented with high-risk disease by IPI). Cytopenias were frequently seen, 
with anaemia being the most common at (69%; 29/42) followed by thrombocytopenia (48%; 
20/42).  Hypoalbuminaemia was frequent among patients with an average albumin level of 28.7 
g/l. Abnormalities in serum creatinine or total bilirubin levels were rare.  
Treatment regimen
The initial treatment course was known for 36 patients (Table III). One patient was noted to have 
received treatment prior to diagnosis. Of the 36 patients who received initial therapy, one was 
treated with surgery alone, and the remaining patients received some form of chemotherapy 
treatment, 23 (64%) obtained CR (one patient achieved this response after 2nd line therapy), 2 
(6%) of patients had a partial response (PR), 7 (19%) had PD and 4 (11%) had unknown 
response.  A total of 18 patients received either no treatment (n=3), were diagnosed post-mortem 
and had no record of treatment prior (n=5), or had no clinical data available in records (n=10).  A 
total of 31 patients received anthracycline-based chemotherapy and 31 received CD20-directed 
therapy with rituximab. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, 
prednisolone) was the most common initial therapy (n=16) with an additional 4 patients also 
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receiving high dose methotrexate.  Other common initial regimens were CHOP (n=4) with 2 
patients reaching CR and 2 achieving PR, and R-CODOX-M (rituximab, cyclophosphamide, 
cytarabine, doxorubicin, vincristine, methotrexate)/R-IVAC (rituximab, ifosfamide, cytarabine, 
etoposide) (n=4) with 3 patients in CR and one death due to sepsis after a single round of 
therapy. R-EPOCH (rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide, 
prednisolone) and rituximab +-hyperCVAD (hyperfractionated cyclophosphamide, vincristine, 
doxorubicin, dexamethasone) were each used in one patient, both achieving CR followed by 
autologous stem cell transplantation (ASCT). The remaining regimens used were: R-DeAngelis 
(n=1 with PD), R-prednisone (n=1 with unknown response), R-dexamethasone (n=1 with PD), 
R-methotrexate (MTX) (N=1 with CR), and ‘high-dose steroids’ (n=1 with PD).  
CNS prophylaxis was provided in 16 (44%) of the patients who received initial therapy (first 
line) with MTX being used in all cases.  Intrathecal MTX was given in 10 of the 16 cases (63%) 
while in the remaining 37% of the cases (n =6) prophylaxis was provided with intravenous high 
dose MTX with varying dosages (3.5 8 g).  Due to the components of the regimens chosen for 
induction therapy, some patients did receive cytarabine. Of note, 1 patient received intrathecal 
cytarabine and three patients received intravenous cytarabine as part of their treatment regimen.
A total of 11 patients received second-line therapy (Table III). R-ICE (rituximab, ifosfamide, 
carboplatin, etoposide) was the most common second line regimen (2 CR; 2 SD). Other regimens 
included hyperCVAD (n=1; CR), R-MVP (rituximab, mitomycin, vinblastine, cisplatin; n=1; 
unknown response), R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin; 
n=1; PR), ICE (n=1; CR), R-EPOCH (n=1; CR), R-MIME (rituximab, mitoguazone, ifosfamide, 
methotrexate, etoposide; n=1; PR), and rituximab alone (n=1; PD). A total of 13 patients 
underwent ASCT, 7 following induction therapy and 6 after a second course of therapy. A single 
patient underwent allogenic stem cell transplantation following relapse after ASCT. 
Survival 
Of the 54 total patients in the study, only 41 patients had a recorded survival time.  As outlined 
in Table IV, 6 (15%) were diagnosed post-mortem and 35 (85%) were diagnosed in vivo. Thirty-
five (65%) of all patients were treated with chemotherapeutic agents. Median OS across all 
patients was 1.08 years (95% CI 0.11, 8.83). Upon further restricting to the 27 patients who were 
diagnosed in vivo and whose treatment status was available, median OS was 5.25 years (95% CI 
1.84, not reached; Figure S1). Comparing these findings to the data that we extracted from 
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previous reports: median OS reported by Brunet, et al (2017) was approximately 0.14 years (all 
diagnoses) and 0.88 years (in vivo diagnoses); in Hong, et al  (2013) it was 3.24 years (in vivo 
diagnoses); in Ferreri, et al (2004) it was 0.52 years (all diagnoses); and in DiGiuseppe, et al 
(1994), it was 1.33 years (in vivo diagnoses, all patients treated with chemotherapy). Figure 1 
compares our survival data with that reported by Brunet et al (2017) and Ferreri et al (2004). The 
shape of the survival curves across all reports was qualitatively similar (Figure 2), characterized 
by an initial steep decrease in survival in the first 1-2 years, and a long-term surviving fraction 
between 20-40%. Murase, et al (2007) only reported survival stratified by CD5 and CD10 status 
but, consistent with the rest of the data, still found that survival at 7 months was approximately 
60%, regardless of CD5/CD10 status, and reported that the 3-year survival rate was 27% for 
those with in vivo diagnosis. 
Prognostic Factors 
Adjusting for age, better performance status at presentation was associated with increased 
survival time for the patients diagnosed in vivo (HR: 2.12, 95% CI 1.28, 3.53; Table V). Due to 
high amounts of missing data, we could not determine if biomarkers were significantly 
associated with survival.
Discussion
While significant advances have been made in the understanding of IVLBCL as a distinct entity 
within non-Hodgkin lymphomas, the rarity of the disease, its heterogeneity, non-specific 
presentation and the limited means available to diagnosis the disease have severely limited 
improvement in clinical outcomes. Thus, this retrospective review, which represents the largest 
collection of cases compiled in the United States to date, provides valuable insight into clinical 
features, outcomes and prognostic factors. A comparison of our findings to those in other recent 
reports suggests qualitatively similar trends in survival. 
This study reaffirms the complex and variable presentation of IVLBCL.  No unifying diagnostic 
signs or symptoms were noted at any of the participating centres, which closely matches 
previous case reports from other North American populations (Brunet et al 2017; Detsky et al 
2006). Of note, neurological and cutaneous involvement was common and, unlike other reported 
cohorts, our study had much higher rates of bone marrow involvement (60% vs 28%). Previous 
retrospective work describing the Asian variant had documented rates of haemophagocytosis 
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reaching 79% (Murase et al 2000). Our study showed that while bone marrow involvement was 
common in this population, the rate of haemophagocytosis was rare, at 11%. Given that no race 
or ethnicity information was collected, further correlation to a particular geographic or hereditary 
background cannot be made and remains a point of further study. 
A wide variability of other immunophenotypic markers has been reported.  CD5 positivity has 
ranged from 23 to 76% in prior literature, compared to 50% in the current study.  Taking into 
account the limitation of the data, our results of this case series appears to correspond with 
previous literature, which has reported a predominantly non- GC COO with a distribution of 
80% non-GC and 20% GC (Murase et al 2007; Shimada et al 2008) compared to 83% and 17% 
in this study.  While the presence of BCL2 and MYC by increased protein expression detectable 
by immunohistochemistry or through genetic rearrangement detected by FISH is known to 
significantly impact outcome, we are unable to confidently make any connection to the patients 
in our data set, again due to limitation of this retrospective study. 
As recently as 1989, over half of IVLBCL cases were diagnosed post mortem. Our study, in 
which the vast majority of cases (five cases with post-mortem diagnosis) have in vivo data after 
diagnosis, represents a large shift in earlier recognition of the disease despite a lack of 
improvement in non-invasive diagnostic tools.  As expected, this is probably critical to patient 
outcomes as ECOG PS at time of diagnosis was independently associated with survival. While 
the median survival for all patients diagnosed in vivo was 5.25 years, this encompasses patients 
receiving a wide range of treatment modalities and also included those who were unable to 
receive therapy. In fact, this more closely aligns with the survival historically expected for 
DLBCL NOS.
In conclusion, while recognizing the limitations of a retrospective study and the variability in 
available patient data illustrated in Figure S2, this study demonstrates a wide degree of 
variability in IVLBCL in the United States and its inability to fit into either of the discreet 
phenotypes previously described.  While future studies with larger populations are needed to 
determine the best approach to therapy, additional research needs to be directed at improving the 
diagnostic modalities that are available to clinicians who treat DLBCL. Newer diagnostic 
modalities, such as circulating tumour DNA (ctDNA) have shown potential to detect DLBCL 
prior to identification using traditional radiographic techniques, such as computed 
tomography/positron emission tomography and has preliminarily been looked at in this difficult 
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patient population (Kurtz et al 2015; Roschewski 2015; Roschewski et al 2015; Suehara et al 
2017).  We believe that techniques such as this might further decrease the time interval from 
symptom onset to disease diagnosis in these patients. Based on the data we have collected, it 
would appear that this time interval is an important contributor to patient outcomes, given that 
longer periods of unrecognized and untreated aggressive lymphoma generally lead to a decline in 
PS and impact the tolerance and ability of the patient to receive appropriate therapy. It is 
possible, based on the limitations of this retrospective study with respect to missing data sets, 
that we could potentially be underestimating the impact that the ability to receive treatment has 
on this patient population but, overall, it would appear that patients who are able to receive 
therapy may not have as dismal an outcome as it generally believed with this diagnosis. 
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Table I. Descriptive statistics. Median (IQR) for continuous data and frequency (% of 
nonmissing data) for count data is included. n=54,
Variable
Total 
Stratified
Median (IQR) or n (%) N missing 
(%)
Age (years), n=53 63.0 (55.0, 69.0) 1 (1.9)
Post-mortem diagnosis (n=6) 74.0 (69.8, 79.0)
In Vivo diagnosis (n=34) 61.0 (53.0, 67.6)
Sex (female), n=53 30 (56.6) 1 (1.9)
Post-mortem diagnosis (n=6) 3 (50.0)
In Vivo diagnosis (n=34) 18 (52.9)
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White blood cell count, n=43 6.0 (3.8, 8.9) 11 (20.4)
Post-mortem diagnosis (n=6) 6.8 (5.0, 8.9)
In Vivo diagnosis (n=30) 5.8 (3.7, 7.7)
Lactate dehydrogenase, n=42 576.0 (338.5, 1459.8) 12 (22.2)
Post-mortem diagnosis (n=6) 1248.5 (712.8, 1707.8)
In Vivo diagnosis (n=27) 596.0 (303.5, 1405.5)
International Prognostic Index, n=40 4.0 (3.0, 5.0) 14 (25.9)
Post-mortem diagnosis (n=6) 5.0 (4.2, 5.0)
In Vivo diagnosis (n=26) 3.5 (3.0, 4.0)
ECOG PS, n=45 2.0 (1.0, 3.0) 9 (16.7)
Post-mortem diagnosis (n=6) 3.5 (3.0, 4.0)
In Vivo diagnosis (n=31) 2.0 (1.0, 3.0)
ECOG PS: Eastern Cooperative Oncology Group performance status; IQR: interquartile range.
Table II. Available immunophenotypic marker information. Counts are stratified by diagnoses 
made in-vivo or post-mortem.
Variable Positive, n (%) Negative, n (%) Missing, n
CD5 Total, n=28 14 (50.0) 14 (50.0) 26
Post-mortem diagnosis 0 2 4
In vivo diagnosis 11 8 16
CD10 Total, n=35 6 (17.1) 29 (82.9) 19
Post-mortem diagnosis 0 3 3
In vivo diagnosis 6 18 11
MUM1 Total, n=21 20 (95.2) 1 (4.8) 33
Post-mortem diagnosis 1 1 4
In vivo diagnosis 12 0 23
BCL6 Total, n=25 14 (56.0) 11 (44.0) 29
Post-mortem diagnosis 0 3 3
In vivo diagnosis 9 6 20
MYC Total, n=8 5 (62.5) 3 (37.5) 46
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Post-mortem diagnosis 0 1 5
In vivo diagnosis 2 1 32
BCL2 Total, n=15 12 (80.0) 3 (20.0) 39
Post-mortem diagnosis 1 0 5
In vivo diagnosis 8 1 26
Table III.  Treatments.
Therapy line Stem cell transplantation
Regimen Initial 2nd 3rd 4th 1st remission 2nd remission 
CHOP +/- R 25 autologous: 7 autologous: 6
allogeneic: 1
R-CODOX-M R-
IVAC
4
R-EPOCH 1 1
Rituximab/Steroids 2
R-DeAngelis 1
R-Hyper-CVAD 1 1
Steroids/XRT 1
Surgery 1
R-MVP 1
R-ESHAP 1
ICE +/- R 5
Rituximab 1
MIME-R 1
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone; CODOX-M: cyclophosphamide, 
cytarabine, doxorubicin, vincristine, methotrexate; EPOCH: etoposide, vincristine, doxorubicin, 
cyclophosphamide, prednisolone; ESHAP: etoposide, methylprednisolone, cytarabine, cisplatin; Hyper-
CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; ICE: ifosfamide, 
carboplatin, etoposide; IVAC: ifosfamide, cytarabine, etoposide; MIME: mitoguazone, ifosfamide, 
methotrexate, etoposide; MVP: mitomycin, vinblastine, cisplatin; R: rituximab; XRT: radiotherapy.
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Table IV. Overall survival time based on patient inclusion
Cohort n Events (death) Median survival time 
(years)
95% confidence 
interval
All patients 41 26 1.84 0.33, 8.83
Patients diagnosed 
in vivo
35 20 5.25 0.58, not reached
Patients who 
received therapy
27 13 5.25 1.84, not reached
Table V. 
Cox regression models for predicting survival after diagnosis fit to the up -to 35 patients 
diagnoses in vivo. All models were adjusted for age at baseline.
Variable n n events Hazard Ratio 95% CI p-value
Age 34 19 1.04 (0.99, 1.09) 0.100
Sex (male) 34 19 2.31 (0.91, 5.84) 0.093
Lactate dehydrogenase 27 17 1.04 (1.00, 1.08) 0.079
White blood cell count 29 18 1.03 (0.99, 1.06) 0.113
International Prognostic Index 25 16 1.49 (0.94, 2.37) 0.092
ECOG PS 30 16 2.12 (1.28, 3.53) 0.004
CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance statusAu
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Figure 1. Kaplan-Meier survival curves from the current study and previous literature of all 
diagnoses including those made post mortem. The studies reported by DiGiuseppe et al (1994) 
and Hong et al (2013) are excluded here because they excluded post-mortem diagnoses. 
    
Figure 2. Survival curves from the current study and previous literature of in vivo diagnoses. The 
survival curves from Murase et al (2007) could not be recreated due to published survival curves 
being stratified. Across the subgroups, the survival probability at 7 months reached 60%.
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